RIGL RIGEL PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1034842 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.2%
TTM net income YoY171.1%
TTM EPS YoY159.6%
Revenue 3-yr CAGR29.6%
Net income 3-yr CAGR—
Margins
Gross margin89.6%
Operating margin26.3%
Net margin106.6%
FCF margin—
EBITDA margin27.6%
Returns
ROE109.2%
ROA80.2%
ROIC (approx.)28.7%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets15.0%
Debt / equity0.00x
Current ratio2.39x
Interest coverage18.17x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio56.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $294.28M | $179.28M |
| Cost of revenue | $19.62M | $18.65M |
| Gross profit | $274.66M | $160.63M |
| R&D expense | $33.30M | $23.38M |
| SG&A expense | $115.90M | $113.06M |
| Operating income | $125.47M | $24.19M |
| Interest expense | $7.32M | $7.92M |
| Pretax income | $121.83M | $18.37M |
| Income tax | -$245.20M | $881,000 |
| Net income | $367.02M | $17.48M |
| EBITDA | $127.88M | $26.42M |
| EPS (basic) | 20.40 | 0.99 |
| EPS (diluted) | 19.48 | 0.99 |
| Weighted avg. shares (diluted) | 18.84M | 17.69M |
| Balance sheet | ||
| Cash & equivalents | $40.58M | $56.75M |
| Short-term investments | $114.38M | $20.57M |
| Receivables | $51.76M | $41.62M |
| Inventory | $11.51M | $6.00M |
| Current assets | $240.17M | $135.10M |
| PP&E, net | $30,000 | $92,000 |
| Intangibles | $24.75M | $27.10M |
| Total assets | $513.59M | $163.98M |
| Current liabilities | $99.24M | $63.30M |
| Long-term debt | $52.50M | $60.00M |
| Total debt | $52.50M | $60.00M |
| Total liabilities | $122.11M | $160.69M |
| Shareholders' equity | $391.48M | $3.29M |
| Net debt | $11.92M | $3.25M |
| Shares outstanding | 18.31M | 17.71M |
| Cash flow statement | ||
| Operating cash flow | $75.66M | $31.47M |
| Investing cash flow | -$92.36M | $4.13M |
| Financing cash flow | $601,000 | -$11.64M |
| Depreciation & amortization | $2.42M | $2.23M |
| Stock-based compensation | $12.71M | $12.39M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.